Promising new therapies in the treatment of advanced ovarian cancer

C. D. Runowicz, A. L. Fields, G. L. Goldberg

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Advanced stage ovarian cancer is the most lethal gynecologic cancer. Despite initial response rates of 60-80% with platinum-based chemotherapy, more than 75% of women with this malignancy die of complications associated with this disease. There is a pressing need to find new chemotherapeutic agents for patients with advanced ovarian cancer. Phase II studies have identified paclitaxel as the most active drug in ovarian cancer since the introduction of cisplatin in the 1970s. Phase III studies will define the role of paclitaxel as initial therapy. Camptothecins (topotecan, CPT-11, 9- amino-camptothecin) inhibit topoisomerase I. CPT-11 and topotecan have shown activity in Phase II trials. Gemcitabine, a pyrimidine antimetabolite, has shown activity in Phase II trials. Other promising drugs (docetaxel, treosulfan) are under investigation. Modulation of drug resistance is being explored in Phase I/II studies. Clinical trials have been initiated with buthionine-sulfoximine, an inhibitor of glutathione biosynthesis, which decreases the ability of resistant cells to inactivate platinum compounds and alkylating agents. Cyclosporin has been shown to increase cisplatin cytotoxicity. Phase I trials have demonstrated the feasibility of combining cyclosporin and cisplatin. Phase II trials of cyclosporin analogs (PSC 833) and paclitaxel in refractory ovarian cancer are ongoing. Promising leads in drug development should provide new therapies for patients with ovarian cancer. Further research in the modulation of drug resistance may identify new mechanisms or strategies with which to prevent the emergence of drug resistance.

Original languageEnglish (US)
Pages (from-to)2028-2033
Number of pages6
JournalCancer
Volume76
Issue number10 SUPPL.
StatePublished - 1995
Externally publishedYes

Fingerprint

irinotecan
Ovarian Neoplasms
Paclitaxel
Drug Resistance
Cisplatin
Cyclosporine
Topotecan
Camptothecin
treosulfan
docetaxel
gemcitabine
Pharmaceutical Preparations
Platinum Compounds
Buthionine Sulfoximine
Therapeutics
Antimetabolites
Type I DNA Topoisomerase
Alkylating Agents
Proxy
Platinum

Keywords

  • antineoplastic agents
  • camptothecins
  • docetaxel
  • gemcitabine
  • ovarian cancer
  • paclitaxel
  • review

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Runowicz, C. D., Fields, A. L., & Goldberg, G. L. (1995). Promising new therapies in the treatment of advanced ovarian cancer. Cancer, 76(10 SUPPL.), 2028-2033.

Promising new therapies in the treatment of advanced ovarian cancer. / Runowicz, C. D.; Fields, A. L.; Goldberg, G. L.

In: Cancer, Vol. 76, No. 10 SUPPL., 1995, p. 2028-2033.

Research output: Contribution to journalArticle

Runowicz, CD, Fields, AL & Goldberg, GL 1995, 'Promising new therapies in the treatment of advanced ovarian cancer', Cancer, vol. 76, no. 10 SUPPL., pp. 2028-2033.
Runowicz CD, Fields AL, Goldberg GL. Promising new therapies in the treatment of advanced ovarian cancer. Cancer. 1995;76(10 SUPPL.):2028-2033.
Runowicz, C. D. ; Fields, A. L. ; Goldberg, G. L. / Promising new therapies in the treatment of advanced ovarian cancer. In: Cancer. 1995 ; Vol. 76, No. 10 SUPPL. pp. 2028-2033.
@article{973b4e86432c463cb410c8f7d372a3ff,
title = "Promising new therapies in the treatment of advanced ovarian cancer",
abstract = "Advanced stage ovarian cancer is the most lethal gynecologic cancer. Despite initial response rates of 60-80{\%} with platinum-based chemotherapy, more than 75{\%} of women with this malignancy die of complications associated with this disease. There is a pressing need to find new chemotherapeutic agents for patients with advanced ovarian cancer. Phase II studies have identified paclitaxel as the most active drug in ovarian cancer since the introduction of cisplatin in the 1970s. Phase III studies will define the role of paclitaxel as initial therapy. Camptothecins (topotecan, CPT-11, 9- amino-camptothecin) inhibit topoisomerase I. CPT-11 and topotecan have shown activity in Phase II trials. Gemcitabine, a pyrimidine antimetabolite, has shown activity in Phase II trials. Other promising drugs (docetaxel, treosulfan) are under investigation. Modulation of drug resistance is being explored in Phase I/II studies. Clinical trials have been initiated with buthionine-sulfoximine, an inhibitor of glutathione biosynthesis, which decreases the ability of resistant cells to inactivate platinum compounds and alkylating agents. Cyclosporin has been shown to increase cisplatin cytotoxicity. Phase I trials have demonstrated the feasibility of combining cyclosporin and cisplatin. Phase II trials of cyclosporin analogs (PSC 833) and paclitaxel in refractory ovarian cancer are ongoing. Promising leads in drug development should provide new therapies for patients with ovarian cancer. Further research in the modulation of drug resistance may identify new mechanisms or strategies with which to prevent the emergence of drug resistance.",
keywords = "antineoplastic agents, camptothecins, docetaxel, gemcitabine, ovarian cancer, paclitaxel, review",
author = "Runowicz, {C. D.} and Fields, {A. L.} and Goldberg, {G. L.}",
year = "1995",
language = "English (US)",
volume = "76",
pages = "2028--2033",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10 SUPPL.",

}

TY - JOUR

T1 - Promising new therapies in the treatment of advanced ovarian cancer

AU - Runowicz, C. D.

AU - Fields, A. L.

AU - Goldberg, G. L.

PY - 1995

Y1 - 1995

N2 - Advanced stage ovarian cancer is the most lethal gynecologic cancer. Despite initial response rates of 60-80% with platinum-based chemotherapy, more than 75% of women with this malignancy die of complications associated with this disease. There is a pressing need to find new chemotherapeutic agents for patients with advanced ovarian cancer. Phase II studies have identified paclitaxel as the most active drug in ovarian cancer since the introduction of cisplatin in the 1970s. Phase III studies will define the role of paclitaxel as initial therapy. Camptothecins (topotecan, CPT-11, 9- amino-camptothecin) inhibit topoisomerase I. CPT-11 and topotecan have shown activity in Phase II trials. Gemcitabine, a pyrimidine antimetabolite, has shown activity in Phase II trials. Other promising drugs (docetaxel, treosulfan) are under investigation. Modulation of drug resistance is being explored in Phase I/II studies. Clinical trials have been initiated with buthionine-sulfoximine, an inhibitor of glutathione biosynthesis, which decreases the ability of resistant cells to inactivate platinum compounds and alkylating agents. Cyclosporin has been shown to increase cisplatin cytotoxicity. Phase I trials have demonstrated the feasibility of combining cyclosporin and cisplatin. Phase II trials of cyclosporin analogs (PSC 833) and paclitaxel in refractory ovarian cancer are ongoing. Promising leads in drug development should provide new therapies for patients with ovarian cancer. Further research in the modulation of drug resistance may identify new mechanisms or strategies with which to prevent the emergence of drug resistance.

AB - Advanced stage ovarian cancer is the most lethal gynecologic cancer. Despite initial response rates of 60-80% with platinum-based chemotherapy, more than 75% of women with this malignancy die of complications associated with this disease. There is a pressing need to find new chemotherapeutic agents for patients with advanced ovarian cancer. Phase II studies have identified paclitaxel as the most active drug in ovarian cancer since the introduction of cisplatin in the 1970s. Phase III studies will define the role of paclitaxel as initial therapy. Camptothecins (topotecan, CPT-11, 9- amino-camptothecin) inhibit topoisomerase I. CPT-11 and topotecan have shown activity in Phase II trials. Gemcitabine, a pyrimidine antimetabolite, has shown activity in Phase II trials. Other promising drugs (docetaxel, treosulfan) are under investigation. Modulation of drug resistance is being explored in Phase I/II studies. Clinical trials have been initiated with buthionine-sulfoximine, an inhibitor of glutathione biosynthesis, which decreases the ability of resistant cells to inactivate platinum compounds and alkylating agents. Cyclosporin has been shown to increase cisplatin cytotoxicity. Phase I trials have demonstrated the feasibility of combining cyclosporin and cisplatin. Phase II trials of cyclosporin analogs (PSC 833) and paclitaxel in refractory ovarian cancer are ongoing. Promising leads in drug development should provide new therapies for patients with ovarian cancer. Further research in the modulation of drug resistance may identify new mechanisms or strategies with which to prevent the emergence of drug resistance.

KW - antineoplastic agents

KW - camptothecins

KW - docetaxel

KW - gemcitabine

KW - ovarian cancer

KW - paclitaxel

KW - review

UR - http://www.scopus.com/inward/record.url?scp=0028860778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028860778&partnerID=8YFLogxK

M3 - Article

C2 - 8634995

AN - SCOPUS:0028860778

VL - 76

SP - 2028

EP - 2033

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10 SUPPL.

ER -